The Latin America, Middle East and Africa Genomics In Cancer Care Market would witness market growth of 17.4% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Genomics In Cancer Care Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $976.1 million by 2031. The Argentina market is showcasing a CAGR of 18.3% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 16.5% during (2024 - 2031).
The growing body of evidence demonstrating the clinical benefits of genomic-based approaches has driven adoption in cancer care. Studies showing improved treatment outcomes, better response rates, and reduced adverse effects associated with genomics-guided therapies have encouraged healthcare providers to incorporate genomic testing into their practice.
Moreover, educational initiatives and training programs for healthcare providers are promoting the adoption of genomics in cancer care. These programs aim to enhance knowledge and skills related to genomic testing, interpretation of results, and integration of genomic information into clinical decision-making. Increased provider education facilitates the adoption of genomics-based approaches in clinical practice.
New healthcare technologies in Saudi Arabia enhance genomic research capabilities, including advanced sequencing technologies and bioinformatics tools. This improvement accelerates the development of genomic solutions for cancer diagnosis and treatment, driving growth in the genomics market. According to the International Trade Administration (ITA), under Vision 2030, the Saudi Arabian Government plans to invest over $65 billion to develop the country’s healthcare infrastructure, reorganize and privatize health services and insurance, launch 21 “health clusters” across the country, and expand the provision of e-health services.
Based on Application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery & Development, and Research. Based on Product, the market is segmented into Instruments, Consumables, Services. Based on Technology, the market is segmented into PCR, Genome Sequencing, Microarrays, Nuclei Acid Extraction & Purification, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Genomics In Cancer Care Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $976.1 million by 2031. The Argentina market is showcasing a CAGR of 18.3% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 16.5% during (2024 - 2031).
The growing body of evidence demonstrating the clinical benefits of genomic-based approaches has driven adoption in cancer care. Studies showing improved treatment outcomes, better response rates, and reduced adverse effects associated with genomics-guided therapies have encouraged healthcare providers to incorporate genomic testing into their practice.
Moreover, educational initiatives and training programs for healthcare providers are promoting the adoption of genomics in cancer care. These programs aim to enhance knowledge and skills related to genomic testing, interpretation of results, and integration of genomic information into clinical decision-making. Increased provider education facilitates the adoption of genomics-based approaches in clinical practice.
New healthcare technologies in Saudi Arabia enhance genomic research capabilities, including advanced sequencing technologies and bioinformatics tools. This improvement accelerates the development of genomic solutions for cancer diagnosis and treatment, driving growth in the genomics market. According to the International Trade Administration (ITA), under Vision 2030, the Saudi Arabian Government plans to invest over $65 billion to develop the country’s healthcare infrastructure, reorganize and privatize health services and insurance, launch 21 “health clusters” across the country, and expand the provision of e-health services.
Based on Application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery & Development, and Research. Based on Product, the market is segmented into Instruments, Consumables, Services. Based on Technology, the market is segmented into PCR, Genome Sequencing, Microarrays, Nuclei Acid Extraction & Purification, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Agilent Technologies, Inc.
- F.Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- GE HealthCare Technologies, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
Market Report Segmentation
By Application- Diagnostics
- Personalized Medicine
- Drug Discovery & Development
- Research
- Instruments
- Consumables
- Services
- PCR
- Genome Sequencing
- Microarrays
- Nuclei Acid Extraction & Purification
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. LAMEA Genomics In Cancer Care Market by Application
Chapter 6. LAMEA Genomics In Cancer Care Market by Product
Chapter 7. LAMEA Genomics In Cancer Care Market by Technology
Chapter 8. LAMEA Genomics In Cancer Care Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- GE HealthCare Technologies, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
Methodology
LOADING...
